Pancreatic Enzyme Supplementation in Patients With Unresectable Pancreatic Cancer (PESUP)
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The investigators planned a prospective, randomized, placebo controlled trial to test the
hypothesis that weight loss in patients with unresectable pancreatic cancer with occlusion of
the pancreatic duct can be reduced or prevented by pancreatic enzyme replacement therapy in
combination with dietary counseling.